Roger Denton Appointed by Federal Judge Herndon to serve as Co-Lead of the Pradaxa Litigation
In an order dated September 27, 2012, Schlichter Bogard and Denton’s partner Roger Denton has been appointed to serve as the Plaintiffs’ Co-Lead Counsel for In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation (MDL 2385). The Pradaxa MDL was created by the U.S. Judicial Panel on Multidistrict Litigation on August 18, 2012. The MDL Panel consolidated all actions which share common factual questions arising out of allegations that plaintiffs suffered severe bleeding or other injuries as a result of taking the drug Pradaxa and that defendants did not adequately warn prescribing physicians of the risks associated with Pradaxa, including the potential for severe or fatal bleeding, and that there is no reversal agent to counteract the Pradaxa’s anticoagulation effects.
As Plaintiffs’ Co-Lead Counsel, Roger is charged with responsibilities including (but not limited to) initiating, coordinating and conducting all pretrial discovery on behalf of all plaintiffs, negotiating and entering into stipulations with defendants regarding the Pradaxa litigation, and acting as a spokesperson for all plaintiffs at pretrial proceedings and in response to any inquires by the Court.
Along with his duties as Co-Lead Counsel, Roger represents individuals who have been injured by Pradaxa. If you or someone you know has been injured by Pradaxa please contact the attorneys at Schlichter Bogard & Denton to discuss your case.